Basic HTML Version
91
SCIENTIFIC REPORT 2012
Publications
BMC Med Genomics
. 2012 Oct 4; 5: 44.
PAM50 breast cancer subtyping by RT-qPCR and
concordance with standard clinical molecular markers
. Bastien RR, Rodríguez-Lescure Á,
Ebbert MT, Prat A, Munárriz B, Rowe L, Miller P, Ruiz-Borrego M, Anderson D, Lyons B,
Alvarez I, Dowell T, Wall D, I Followed MA, Barley L, Boucher KM, Alba E, Pappas L, Davis CA,
Aranda I, Fauron C, Stijleman IJ, Palacios J, Antón A, Carrasco E, Caballero R, Ellis MJ,
Nielsen TO, Peru CM, Astill M, Bernard PS, Martín M.
Breast Cancer Nothing Treated
. 2012 Apr;132(3):819-31.
CD24 Ala57Val polymorphism predicted
pathological complete response to sequential anthracycline- and taxane-based
neoadjuvant chemotherapy for primary breast cancer
. Marmé F, Werft W, Walter A, Keller
S, Wang X, Benner A, Burwinkel B, Sinn P, Hug S, Sohn C, Bretz N, Moldenhauer G, Rupp C,
Rupp AK, Biakhov MY, Bottini A, Friedrichs K, Khailenko VA, Manikhas GM, Ruiz A, Sánchez-
Rovira P, Santoro A, Follow MA, Villena C, Lichter P, Kristiansen G, Altevogt P, Schneeweiss A.
Mutagenesis
. 2012 Nov;27(6):771-7.
Relevance of GSTM1, GSTT1, and GSTP1 gene
polymorphisms to gastric cancer susceptibility and phenotype
. García-González MA,
Quintero E, Bujanda L, Nicolás D, Benito R, Strunk M, Santolaria S, Sopeña F, Badía M, Hijona
E, Pérez-Aísa MA, Méndez-Sánchez IM, Thomson C, Carrera P, Piazuelo E, Jiménez P,
Espinel J, Campo R, Manzano M, Geijo F, Pellisé M, González-Huix F, Espinós J, Titó L,
Zaballa M, Pazo R, Lanas A.
Cancer | Clinical and translational research
Projects
Title:
Multicenter, randomized, double-blind, placebo-controlled phase II study for
to investigate two doses of EMD 525797 in asymptomatic or mildly symptomatic patients, with
castration-resistant metastatic prostate cancer (CPRCm).
District Attorney:
Merck KgaA.
Principal Investigator:
Teresa Bonfill Abella.
Title:
Phase III randomized, multicenter, double-blind, placebo-controlled study for
evaluate the efficacy and safety of MetMAb in combination with Tarceva® (Erlotinib) in
patients with non - small cell lung cancer (PCNM) with tumors positive for it
diagnosis of Met and who have received the usual chemotherapy for the treatment of
advanced or metastatic disease.
District Attorney:
Genentech, Inc.
Principal Investigator:
Elsa Dalmau Pórtulas.